Proline-containing dipeptide nootropic studied for cognitive enhancement, neuroprotection, and anxiety reduction. Developed in Russia. Rapidly crosses BBB; active at nanogram doses. Different mechanism from racetam class.
Very short plasma half-life (~5 minutes); CNS activity much longer due to cycloprolylglycine conversion
SKUs
1
Evidence
Preliminary
Noopept is a synthetic dipeptide developed in Russia that is structurally related to the racetam family of nootropic compounds. It has been studied for cognitive enhancement, neuroprotection, and Alzheimer's disease research, primarily through Russian institutions. It is considered a potent compound relative to similar molecules — small doses are thought to be effective — and it appears to cross the blood-brain barrier readily.
Cognitive Enhancement Research
Russian studies have examined Noopept in patients with mild cognitive impairment and post-stroke cognitive decline. Some randomized trials reported improvements in cognitive function scores, memory, and attention. However, most studies are from Russian institutions and have not been replicated in large Western trials.
Neuroprotective Research
Cell culture and animal studies show Noopept has neuroprotective properties, including protection against amyloid toxicity relevant to Alzheimer's disease research and protection against oxidative stress in neural tissue.
Anxiety and Mood Research
Some research has examined Noopept for anxiolytic effects. Animal studies showed reduced anxiety-like behavior. This has contributed to anecdotal reports from users of mood-calming effects alongside cognitive effects.
Russian clinical trials show improvements in cognitive scores in mild cognitive impairment patients.
Animal and cell culture studies show neuroprotective effects against multiple insult types.
Appears brain-penetrant and active at relatively small doses compared to related compounds.
Evidence from large independent Western trials is absent.
Most clinical research is from Russian institutions and has not been independently replicated. Trial quality and reporting standards in the published literature vary. Noopept is not approved by the FDA or EMA. It is sold as a supplement in some jurisdictions and as a drug requiring prescription in others (notably Russia). The long-term safety profile in humans is not established.
Noopept is metabolized in the body to a small peptide called cycloprolylglycine, which is thought to be its active form in the brain. Research suggests it enhances neurotrophic signaling — specifically, it appears to increase the expression of BDNF and NGF, proteins that support neuron growth, survival, and the formation of new connections. It may also modulate acetylcholine and glutamate signaling, both of which are heavily involved in memory and learning. Unlike racetam compounds that primarily affect acetylcholine, Noopept's mechanism is thought to be broader, which may explain why it appears active at very small doses relative to its structural relatives.
Noopept has been used in clinical studies without significant safety signals emerging. Side effects reported include headache and irritability at higher doses. It is not FDA-approved. The long-term safety profile in healthy individuals using it as a cognitive supplement is not established by clinical trial data. It is legally sold as a supplement in many countries but its regulatory status varies significantly by jurisdiction.
Preliminary
Most evidence comes from preclinical studies and case reports. Human data is limited and more research is needed.
Published Research Ranges
10–30mg/day oral or intranasal in Russian clinical research; intranasal may provide better CNS delivery
Research Context Only: These are ranges reported in published scientific studies for educational reference. They are not dosing recommendations. This is not medical advice. Always consult a qualified healthcare professional.
Sources listed here are from the platform research library. All links open the original publication. No citations are generated by AI.
Noopept Stimulates Expression of NGF and BDNF in Rat Hippocampus
Bulletin of Experimental Biology and Medicine • 2008
• DOI: 10.1007/s10517-008-0297-x
Physicochemical and structural analysis of N-phenylacetyl-L-prolylglycine ethyl ester (Noopept) - An active pharmaceutical ingredient with nootropic activity
Noopept; a nootropic dipeptide, modulates persistent inflammation by effecting spinal microglia dependent Brain Derived Neurotropic Factor (BDNF) and pro-BDNF expression throughout apoptotic process
Neuroprotective effect of novel cognitive enhancer noopept on AD-related cellular model involves the attenuation of apoptosis and tau hyperphosphorylation
The nootropic and neuroprotective proline-containing dipeptide noopept restores spatial memory and increases immunoreactivity to amyloid in an Alzheimer's disease model
Unraveling Molecular and Genetic Insights into Neurodegenerative Diseases: Advances in Understanding Alzheimer's, Parkinson's, and Huntington's Diseases and Amyotrophic Lateral Sclerosis
The Occurrence of Illicit Smart Drugs or Nootropics in Europe and Australia and Their Associated Dangers: Results from a Market Surveillance Study by 12 Official Medicines Control Laboratories
Research Education Only: This profile is for educational purposes only. All information is sourced from published scientific literature. This is not medical advice. Not for human consumption. Consult qualified medical professionals for any health decisions.
We use cookies to enhance your research experience and analyze platform usage. By continuing, you agree to our Cookie Policy.